Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Genentech a member of the Roche Group announced today that the Phase IIIII SKYSCRAPER study evaluating tiragolumab plus Tecentriq and chemotherapy
GSK plc and CureVac NV today announced they have restructured their existing collaboration into a new licensing agreement allowing each company to prioritise investment and focus their respective mRNA development activities
Regeneron Pharmaceuticals Inc and Sanofi today announced that the European Commission has approved Dupixent as an addon maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease
Fresenius via its operating company Fresenius Kabi announced today the immediate availability in the US of its biosimilar Tyenne in a subcutaneous
Vertex Pharmaceuticals Incorporated today announced that the US Food and Drug Administration has accepted its New Drug Application for investigational
Heron Therapeutics Inc a commercialstage biotechnology company today announced that the FDA acknowledged the receipt of the Companys Prior
The US Food and Drug Administration approved Kisunla Eli Lilly and Companys Alzheimers treatment for adults with early symptomatic Alzheimers disease which includes people with mild cognitive impairment as well as people
Kashiv BioSciences LLC today announced that it has entered into an exclusive licensing agreement for ADL a proposed biosimilar to omalizumab referencing
Ovid Therapeutics Inc a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies
Biophytis SA a clinicalstage biotechnology company specialized in the development of therapeutics for agerelated diseases presented the rollout and results of its phase COVA